Overview
Babesiosis is an infectious disease caused by intraerythrocytic protozoan parasites of the genus Babesia, transmitted primarily through the bite of infected Ixodes ticks (the same ticks that transmit Lyme disease). The most common species affecting humans are Babesia microti in North America and Babesia divergens in Europe. The disease can also be transmitted through contaminated blood transfusions or, rarely, through congenital (transplacental) transmission. Babesiosis primarily affects the hematologic system, as the parasites invade and destroy red blood cells, leading to hemolytic anemia. Key symptoms include fever, chills, sweats, fatigue, malaise, headache, and myalgia, typically appearing one to four weeks after a tick bite. Laboratory findings commonly reveal hemolytic anemia, thrombocytopenia, elevated liver enzymes, and elevated lactate dehydrogenase. Many infected individuals, particularly those who are immunocompetent, may remain asymptomatic or experience only mild illness. However, the disease can be severe and life-threatening in immunocompromised individuals (especially those who are asplenic, elderly, or receiving immunosuppressive therapy), with complications including acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, and splenic rupture. Treatment depends on disease severity. For mild to moderate cases, the standard regimen is a combination of atovaquone and azithromycin for 7 to 10 days. For severe cases, the preferred treatment is intravenous clindamycin combined with oral quinine, along with supportive care including red blood cell exchange transfusion in cases of high parasitemia (typically greater than 10%), severe hemolysis, or organ compromise. Immunocompromised patients may require prolonged courses of antimicrobial therapy. Prevention strategies focus on tick avoidance measures and screening of blood donations in endemic areas.
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
3 eventsUniversity Hospital, Strasbourg, France
60 Degrees Pharmaceuticals LLC — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Babesiosis.
3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Babesiosis.
Community
No community posts yet. Be the first to share your experience with Babesiosis.
Start the conversation →Latest news about Babesiosis
Disease timeline:
New recruiting trial: Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
A new clinical trial is recruiting patients for Babesiosis
New recruiting trial: Human Babesiosis in Metropolitan France
A new clinical trial is recruiting patients for Babesiosis
New recruiting trial: B-FREE Chronic Babesiosis Study
A new clinical trial is recruiting patients for Babesiosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Babesiosis
What is Babesiosis?
Babesiosis is an infectious disease caused by intraerythrocytic protozoan parasites of the genus Babesia, transmitted primarily through the bite of infected Ixodes ticks (the same ticks that transmit Lyme disease). The most common species affecting humans are Babesia microti in North America and Babesia divergens in Europe. The disease can also be transmitted through contaminated blood transfusions or, rarely, through congenital (transplacental) transmission. Babesiosis primarily affects the hematologic system, as the parasites invade and destroy red blood cells, leading to hemolytic anemia.
Are there clinical trials for Babesiosis?
Yes — 3 recruiting clinical trials are currently listed for Babesiosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Babesiosis?
2 specialists and care centers treating Babesiosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.